col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


207 Results       Page 1

 [1] 
Elsevier: Biomedicine & Pharmacotherapy
  original article Date Title Authors   All Authors
1 [GO] 2025―Jan―24 Subphenotypes of Long COVID and the clinical applications of probiotics Hui Xuan Lim, Kanwal Khalid, Amar Daud Iskandar Abdullah, Learn-Han Lee, Raja Affendi Raja Ali
2 [GO] 2024―Oct―22 Therapeutic oligonucleotide ASC1R shows excellent tolerability and remarkable efficacy in reducing SARS-CoV-2 mRNA levels in C57BL/6 mice Veronika Nemethova, Petra Babiakova, Michal Selc, Kristina Jakic, Lucia Uhelska, Boglarka Teglasova, et al. (+3)
3 [GO] 2024―Oct―01 Identification of nitrile-containing isoquinoline-related natural product derivatives as coronavirus entry inhibitors in silico and in vitro Nasim Shahhamzehei, Sara Abdelfatah, Hannah S. Schwarzer-Sperber, Kathrin Sutter, Rümeysa Yücer, Gerhard Bringmann, et al. (+2)
4 [GO] 2024―Sep―19 Macrolide resistance outcomes after the Covid-19 pandemic: A one health approach investigation Sarah O. Rodrigues, Felipe R. Santiago, Monique S. Silva, Alex Sandro G. Lima, Lidiane E. Godoy, Michel De Waard, et al. (+4)
5 [GO] 2024―Aug―26 Retraction notice to 'Deaths induced by compassionate use of hydroxychloroquine during the first COVID-19 wave: an estimate' [Biomedicine & Pharmacotherapy, Volume 171 (2024) 116055] Alexiane Pradelle, Sabine Mainbourg, Steeve Provencher, Emmanuel Massy, Guillaume Grenet, Jean-Christophe Lega
6 [GO] 2024―Aug―03 Corrigendum to: “Changes in the immune response against SARS-CoV-2 in individuals with severe COVID-19 treated with high dose of vitamin D” [Biomed. Pharmacother. 150 (2022) 1-11] Montserrat Torres, Guiomar Casado, Lorena Vigón, Sara Rodríguez-Mora, Elena Mateos, Fernando Ramos-Martín, et al. (+7)
7 [GO] 2024―Jun―10 Antibody drugs targeting SARS-CoV-2: Time for a rethink? Likeng Liang, Bo Wang, Qing Zhang, Shiwu Zhang, Sihe Zhang
8 [GO] 2024―May―24 Repurposing anti-cancer porphyrin derivative drugs to target SARS-CoV-2 envelope Diogo A. Mendonça, Iris Cadima-Couto, Carolina C. Buga, Zoe A. Arnaut, Fabio A. Schaberle, Luis G. Arnaut, et al. (+2)
9 [GO] 2024―Mar―21 Intranasal administration of Escherichia coli Nissle expressing the spike protein of SARS-CoV-2 induces long-term immunization and prevents spike protein-mediated lung injury in mice Giovanni Sarnelli, Alessandro Del Re, Irene Palenca, Silvia Basili Franzin, Jie Lu, Luisa Seguella, et al. (+6)
10 [GO] 2024―Mar―15 Novel nitric oxide donors are coronary vasodilators that also bind to the papain-like protease of SARS-CoV-2 John F. Schmedtje, Fred Ciske, Kendall M. Muzzarelli, Zahra Assar
11 [GO] 2024―Mar―13 Emerging role of N6-methyladenosine RNA modification in regulation of SARS-CoV-2 infection and virus-host interactions Jiayi Liu, Lingli Chen, Xiongmin Guo, Bingrong Zhao, Juan Jiang
12 [GO] 2024―Feb―09 Assessing medication use patterns by clinical outcomes severity among inpatients with COVID-19: A retrospective drug utilization study Renato Ferreira-da-Silva, Priscila Maranhão, Cláudia Camila Dias, João Miguel Alves, Lígia Pires, Manuela Morato, et al. (+2)
13 [GO] 2024―Jan―28 Editor’s Note on “Deaths induced by compassionate use of hydroxychloroquine during the first COVID-19 wave: An estimate” [Biomed. Pharmacother. 171 (2024) 116055] Alexiane Pradelle, Sabine Mainbourg, Steeve Provencher, Emmanuel Massy, Guillaume Grenet, Jean-Christophe Lega
14 [GO] 2024―Jan―23 Recent advancements in the discovery of small-molecule non-nucleoside inhibitors targeting SARS-CoV-2 RdRp Bangdi Zhou, Dianming Chen, Tingyan Zhang, Chenggui Song, Xianwu Zhang, Leying Lin, et al. (+6)
15 [GO] 2024―Jan―22 Myocarditis and pericarditis risk with mRNA COVID-19 vaccination compared to unvaccinated individuals: A retrospective cohort study in a Spanish Tertiary Hospital Mikel Urroz Elizalde, Francisco Javier Guijarro Eguinoa, Arturo Gómez López de las Huertas, María Jiménez-González, Elena Ramírez
16 [GO] 2024―Jan―09 Immunoregulatory effects of nanocurcumin in inflammatory milieu: Focus on COVID-19 Fahimeh Lavi Arab, Akram Hoseinzadeh, Fatemeh Sadat Mohammadi, Arezoo Rajabian, Arezoo Faridzadeh, Mahmoud Mahmoudi
17 [GO] 2024―Jan―02 Deaths induced by compassionate use of hydroxychloroquine during the first COVID-19 wave: an estimate Alexiane PRADELLE, Sabine MAINBOURG, Steeve PROVENCHER, Emmanuel MASSY, Guillaume GRENET, Jean-Christophe LEGA
18 [GO] 2023―Dec―12 Effect of salidroside on neuroprotection and psychiatric sequelae during the COVID-19 pandemic: A review Ting Zhu, Hui Liu, Shiman Gao, Ning Jiang, Shuai Chen, Weijie Xie
19 [GO] 2023―Dec―07 Inhibition of SARS-CoV-2 infection and replication by Petasites hybridus CO2-extract (Ze 339) Constanze A. Jakwerth, Vincent Grass, Anna Erb, Andreas Pichlmair, Georg Boonen, Veronika Butterweck, Carsten B. Schmidt-Weber
20 [GO] 2023―Nov―25 Inhibition of furin-like enzymatic activities and SARS-CoV-2 infection by osthole and phenolic compounds with aryl side chains Yuka Kiba, Takashi Tanikawa, Tsuyoshi Hayashi, Hitoshi Kamauchi, Taishi Seki, Ryuichiro Suzuki, Masashi Kitamura
21 [GO] 2023―Nov―21 Adjunctive use of oral MAF is associated with no disease progression or mortality in hospitalized patients with COVID-19 pneumonia: The single-arm COral-MAF1 prospective trial Lucrezia Spadera, Marina Lugarà, Maria Spadera, Mariano Conticelli, Gabriella Oliva, Vincenzo Bassi, et al. (+14)
22 [GO] 2023―Oct―14 The potential role of ferroptosis in COVID-19-related cardiovascular injury Lei Yang, Yunyi Wu, Weidong Jin, Nan Mo, Gaoqi Ye, Zixin Su, et al. (+4)
23 [GO] 2023―Oct―11 Antiviral, virucidal and antioxidant properties of Artemisia annua against SARS-CoV-2 Melissa Baggieri, Silvia Gioacchini, Gigliola Borgonovo, Giorgia Catinella, Antonella Marchi, Pasquale Picone, et al. (+11)
24 [GO] 2023―Sep―23 Is neuropilin-1 the neuroimmune initiator of multi-system hyperinflammation in COVID-19? Kiarash Saleki, Parsa Alijanizadeh, Abbas Azadmehr
25 [GO] 2023―Aug―17 Role of SARS-COV-2 and ACE2 in the pathophysiology of peripheral vascular diseases Hamid Tanzadehpanah, Elham Lotfian, Amir Avan, Sahar Saki, Sima Nobari, Roghaye Mahmoodian, et al. (+5)
26 [GO] 2023―Aug―09 Eculizumab suppresses zymosan-induced release of inflammatory cytokines IL-1α, IL-1β, IFN-γ and IL-2 in autologous serum-substituted PBMC cultures: Relevance to cytokine storm in Covid-19 Tamás Bakos, Gergely T. Kozma, János Szebeni, Gábor Szénási
27 [GO] 2023―Aug―03 Impact of methotrexate treatment on vaccines immunogenicity in adult rheumatological patients - Lessons learned from the COVID-19 pandemic Jakub Wroński, Marzena Ciechomska, Ewa Kuca-Warnawin
28 [GO] 2023―Jun―30 Exploring the future of SARS-CoV-2 treatment after the first two years of the pandemic: A comparative study of alternative therapeutics Benjamin Babalola, Oluwamayowa Samuel Akinsuyi, Elizabeth Moyosoreoluwa Folajimi, Folakemi Olujimi, Ahmed Adebisi Otunba, Bruno Chikere, et al. (+2)
29 [GO] 2023―Jun―08 β-Cyclodextrins as affordable antivirals to treat coronavirus infection Dalia Raïch-Regué, Raquel Tenorio, Castro Isabel Fernández de, Ferran Tarrés-Freixas, Martin Sachse, Daniel Perez-Zsolt, et al. (+21)
30 [GO] 2023―May―15 The F/B ratio as a biomarker for inflammation in COVID-19 and T2D: Impact of metformin Pavlo Petakh, Valentyn Oksenych, Aleksandr Kamyshnyi
31 [GO] 2023―May―09 Fibrinolytic system and COVID-19: From an innovative view of epithelial ion transport Yunmei Fu, Hao Xue, Tingyu Wang, Yan Ding, Yong Cui, Hongguang Nie
32 [GO] 2023―May―05 Intravenous immunoglobulins (IVIG) in severe/critical COVID-19 adult patients. Dorota Kwapisz, Joanna Bogusławska
33 [GO] 2023―Apr―27 Corrigendum to “Factors regulating dynamics of angiotensin-converting enzyme-2 (ACE2), the gateway of SARS-CoV-2: Epigenetic modifications and therapeutic interventions by epidrugs” Biomed. Pharmacother. 143 (2021) 112095 Suvasmita Rath, Venkateswarlu Perikala, Atala Bihari Jena, Jagneshwar Dandapat
34 [GO] 2023―Apr―13 Dendrobium officinale aqueous extract influences the immune response following vaccination against SARS-CoV-2 Xiaoping Gao, Ting Ye, Yu Lei, Qi Zhang, Yuanning Luo, Haiyan Yang, et al. (+6)
35 [GO] 2023―Apr―07 Reports analysis of psychotropic drugs related adverse reactions in Australia and Poland during the COVID 19 pandemic Schetz Daria, Scott Tara Elizabeth, Waldman Wojciech, Sein Anand Jacek, Wiergowski Marek, Kocić Ivan
36 [GO] 2023―Mar―31 Lung mesenchymal cells from patients with COVID-19 driven lung fibrosis: Several features with CTD-ILD derived cells but with higher response to fibrogenic signals and might be more pro-inflammatory Sara Bozzini, Matteo Della Zoppa, Cecilia Bagnera, Eleonora Bozza, Stefania Croce, Chiara Valsecchi, et al. (+6)
37 [GO] 2023―Mar―28 Identification of FDA Approved Drugs with Antiviral Activity against SARS-CoV-2: A Tale from structure-based drug repurposing to host-cell mechanistic investigation Mahmoud S. Ahmed, Ayman B. Farag, Ian N. Boys, Ping Wang, Ivan Menendez-Montes, Ngoc Uyen Nhi Nguyen, et al. (+14)
38 [GO] 2023―Mar―10 Ovatodiolide inhibits SARS-CoV-2 replication and ameliorates pulmonary fibrosis through suppression of the TGF-β/TβRs signaling pathway Wei-Chung Chiou, Guan-Jhong Huang, Tein-Yao Chang, Tzu-Lan Hsia, Hao-You Yu, Jir-Mehng Lo, et al. (+2)
39 [GO] 2023―Feb―06 Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy? Seyed Mohammad Reza Hashemian, Amirhossein Sheida, Mohammad Taghizadieh, Mohammad Yousef Memar, Michael R Hamblin, Hossein Bannazadeh Baghi, et al. (+3)
40 [GO] 2023―Jan―23 Bmal1 and Gut-lung axis in SARS-CoV-2 infection: new insight into the effects of melatonin on COVID-19 patients? Mohammad Rafi Khezri, Reza Varzandeh, Morteza Ghasemnejad-Berenji
41 [GO] 2023―Jan―16 Computer-aided drug design for the Pain-Like protease (PLpro) inhibitors against SARS-CoV-2 Hongwei Gao, Renhui Dai, Ruiling Su
42 [GO] 2023―Jan―11 SARS-CoV-2 E protein: pathogenesis and potential therapeutic development Shilin Zhou, Panpan Lv, Mingxue Li, Zihui Chen, Hong Xin, Svetlana Reilly, Xuemei Zhang
43 [GO] 2023―Jan―02 From Immunogen to COVID-19 vaccines: Prospects for the post-pandemic era Ganggang Miao, Zhiqiang Chen, Hengsong Cao, Wenhao Wu, Xi Chu, Hanyuan Liu, et al. (+7)
44 [GO] 2022―Dec―16 The influence of the COVID-19 pandemic on the prescription of multiple sclerosis medication in Germany Jonathan Orschiedt, Elizabeth Jacyshyn-Owen, Maria Kahn, Sven Jansen, Natalie Joschko, Markus Eberl, et al. (+3)
45 [GO] 2022―Dec―09 Humulus lupus extract rich in xanthohumol improves the clinical course in critically ill COVID-19 patients Wojciech Dabrowski, Mariusz Gagos, Dorota Siwicka-Gieroba, Mariusz Piechota, Jan Siwiec, Magdalena Bielacz, et al. (+5)
46 [GO] 2022―Dec―05 A potential host and virus targeting tool against COVID-19: Chemical characterization, antiviral, cytoprotective, antioxidant, respiratory smooth muscle relaxant effects of Paulownia tomentosa Steud Fabio Magurano, Matteo Micucci, Domenico Nuzzo, Melissa Baggieri, Pasquale Picone, Silvia Gioacchini, et al. (+15)
47 [GO] 2022―Nov―07 Mutations in SARS-CoV-2: Insights on structure, variants, vaccines, and biomedical interventions Ahmed I. Abulsoud, Hussein M. El-Husseiny, Ahmed A. El-Husseiny, Hesham A. El-Mahdy, Ahmed Ismail, Samy Y. Elkhawaga, et al. (+11)
48 [GO] 2022―Oct―31 Identification of phytochemicals in Qingfei Paidu decoction for the treatment of coronavirus disease 2019 by targeting the virus-host interactome Yuyun Li, Yan Wu, Siyan Li, Yibin Li, Xin Zhang, Zeren Shou, et al. (+8)
49 [GO] 2022―Oct―17 The role of SARS-CoV-2 accessory proteins in immune evasion Milad Zandi, Maryam Shafaati, Davood Kalantar-Neyestanaki, Hossein Pourghadamyari, Mona Fani, Saber Soltani, et al. (+2)
50 [GO] 2022―Oct―11 Highly pathogenic coronaviruses and the kidney Fang Wang, Xiao-Guo Suo, Cong Wang, Jia-Nan Wang, Xiao-Yan He, Fa-Cai Wang, et al. (+5)
51 [GO] 2022―Sep―28 Ganoderma microsporum immunomodulatory protein acts as a multifunctional broad-spectrum antiviral against SARS-CoV-2 by interfering virus binding to the host cells and spike-mediated cell fusion Ha Phan Thanh Ho, Di Ngoc Kha Vo, Tung-Yi Lin, Jo-Ning Hung, Ya-Hui Chiu, Ming-Han Tsai
52 [GO] 2022―Aug―31 The landscape of potential health benefits of carotenoids as natural supportive therapeutics in protecting against Coronavirus infection Louise W. Lu, Yao Gao, Siew-Young Quek, Meika Foster, Charles T. Eason, Min Liu, et al. (+3)
53 [GO] 2022―Aug―30 Genome-wide transcriptional profiling of pulmonary functional sequelae in ARDS- secondary to SARS-CoV-2 infection María C. García-Hidalgo, Rafael Peláez, Jessica González, Sally Santisteve, Iván D. Benítez, Marta Molinero, et al. (+24)
54 [GO] 2022―Aug―22 The favorable impacts of silibinin polyphenols as adjunctive therapy in reducing the complications of COVID-19: A review of research evidence and underlying mechanisms Vali Musazadeh, Arash Karimi, Nasim bagheri, Jaber Jafarzadeh, Sarvin Sanaei, Mahdi Vajdi, et al. (+2)
55 [GO] 2022―Aug―17 Cerebral microvascular complications associated with SARS-CoV-2 infection: How did it occur and how should it be treated? Neda Omidian, Pantea Mohammadi, Mona Sadeghalvad, Hamid-Reza Mohammadi-Motlagh
56 [GO] 2022―Aug―17 COVID-19-associated Liver Injury: Clinical Characteristics, Pathophysiological Mechanisms and Treatment Management Penghui Li, Ying Liu, Ziqi Cheng, Xiaorui Yu, Yinxiong Li
57 [GO] 2022―Aug―15 Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2? Manish Dhawan, AbdulRahman A. Saied, Saikat Mitra, Fahad A. Alhumaydhi, Talha Bin Emran, Polrat Wilairatana
58 [GO] 2022―Aug―12 Recent advances in point of care testing for COVID-19 detection Renata Salgado Fernandes, Juliana de Oliveira Silva, Karina Braga Gomes, Ricardo Bentes Azevedo, Danyelle M Townsend, Adriano de Paula Sabino, Andre Luis Branco de Barros
59 [GO] 2022―Aug―02 A comprehensive insight into current control of COVID-19: Immunogenicity, vaccination, and treatment. Yasser Mohamed, Yousra A. El-Maradny, Ahmed K. Saleh, AbdElAziz A. Nayl, Hamada El-Gendi, Esmail M. El-Fakharany
60 [GO] 2022―Jul―21 Early reduction of estimated Glomerular Filtration Rate (eGFR) predicts poor outcome in acutely ill hospitalized COVID-19 patients firstly admitted to medical regular wards (eGFR-COV19 study). Francesco Cei, Ludia Chiarugi, Simona Brancati, Maria Silvia Montini, Silvia Dolenti, Daniele Di Stefano, et al. (+14)
61 [GO] 2022―Jul―18 Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses Paul Andrei Negru, Denisa Claudia Miculas, Tapan Behl, Alexa Florina Bungau, Ruxandra-Cristina Marin, Simona Gabriela Bungau
62 [GO] 2022―Jul―18 Study on the potential of Sanghuangporus sanghuang and its components as COVID-19 spike protein receptor binding domain inhibitors Liang-Hsuan Chien, Jeng-Shyan Deng, Wen-Ping Jiang, Chin-Chu Chen, Ya-Ni Chou, Jaung-Geng Lin, Guan-Jhong Huang
63 [GO] 2022―Jul―11 Epigenetic activation of antiviral sensors and effectors of interferon response pathways during SARS-CoV-2 infection Jan Bińkowski, Olga Taryma-Leśniak, Karolina Łuczkowska, Anna Niedzwiedź, Kacper Lechowicz, Dominik Strapagiel, et al. (+8)
64 [GO] 2022―Jun―30 Molecular mechanisms involved in pathogenicity of SARS-CoV-2: Immune evasion and implications for therapeutic strategies Hatixhe Latifi-Pupovci
65 [GO] 2022―Jun―28 A comprehensive review of artificial intelligence and network based approaches to drug repurposing in Covid-19 Faheem Ahmed, Afaque Manzoor Soomro, Abdul Rahim Chethikkattuveli Salih, Anupama Samantasinghar, Arun Asif, In Suk Kang, Kyung Hyun Choi
66 [GO] 2022―Jun―02 Treatment with metformin glycinate reduces SARS-CoV-2 viral load: an in vitro model and randomized, double-blind, Phase IIb clinical trial Claudia Ventura-López, Karla Cervantes-Luevano, Janet S. Aguirre-Sánchez, Juan C. Flores-Caballero, Carolina Alvarez-Delgado, Johanna Bernaldez-Sarabia, et al. (+8)
67 [GO] 2022―May―30 SOLVx therapeutics vaccine - Activate T-cell immunity using broad surveillance epitope strategy against mutant strains SARS-COV2 Md Shamsuddin Sultan Khan, John A. Catanzaro
68 [GO] 2022―May―27 Plasmatic renin-angiotensin system in normotensive and hypertensive patients hospitalized with COVID-19 Mauro G. Silva, Gerardo R. Corradi, Juan I. Pérez Duhalde, Myriam Nuñez, Eliana M. Cela, Daniel H. Gonzales Maglio, et al. (+4)
69 [GO] 2022―May―24 Reviving the mutual impact of SARS-COV-2 and obesity on patients: From morbidity to mortality Tapan Behl, Sachin Kumar, Sukhbir Singh, Saurabh Bhatia, Ali Albarrati, Mohammed Albratty, et al. (+3)
70 [GO] 2022―May―24 Self-derived peptides from the SARS-CoV-2 spike glycoprotein disrupting shaping and stability of the homotrimer unit Monikaben Padariya, Alison Daniels, Christine Tait-Burkard, Ted Hupp, Umesh Kalathiya
71 [GO] 2022―May―16 High-throughput drug screening allowed identification of entry inhibitors specifically targeting different routes of SARS-CoV-2 Delta and Omicron Maria Kuzikov, Jannis Woens, Andrea Zaliani, Julia Hambach, Thomas Eden, Boris Fehse, et al. (+2)
72 [GO] 2022―May―16 Immune-based therapeutic approaches in COVID-19 Aysan Moeinafshar, Niloufar Yazdanpanah, Nima Rezaei
73 [GO] 2022―May―08 COVID-19 and Diabetes: Association Intensify Risk Factors for Morbidity and Mortality Prateek Sharma, Tapan Behl, Neelam Sharma, Sukhbir Singh, Ajmer Singh Grewal, Ali Albarrati, et al. (+3)
74 [GO] 2022―May―02 Molnupiravir combined with different repurposed drugs further inhibits SARS-CoV-2 infection in human nasal epithelium in vitro Hulda R. Jonsdottir, Denise Siegrist, Thomas Julien, Blandine Padey, Mendy Bouveret, Olivier Terrier, et al. (+8)
75 [GO] 2022―Apr―26 Seroprevalence of SARS-CoV-2-specific antibodies and vaccination-related adverse events in systemic lupus erythematosus and rheumatoid arthritis Peng Wang, Jing Ni, Ya-Ya Chu, Qing-Qing Chen, Guo-Cui Wu, Yang Fang, et al. (+9)
76 [GO] 2022―Apr―25 Ursodeoxycholic acid ameliorates cell migration retarded by the SARS-CoV-2 spike protein in BEAS-2B human bronchial epithelial cells Pham Xuan Thuy, Tran Duc Duy Bao, Eun-Yi Moon
77 [GO] 2022―Apr―15 Adamalysins in COVID-19 - Potential Mechanisms Behind Exacerbating the Disease Ivo Ricardo de Seabra Rodrigues Dias, Zhijian Cao, Hang Fai Kwok
78 [GO] 2022―Apr―14 Changes in the immune response against SARS-CoV-2 in individuals with severe COVID-19 treated with high dose of vitamin D Montserrat Torres, Guiomar Casado, Lorena Vigón, Sara Rodríguez-Mora, Elena Mateos, Fernando Ramos-Martín, et al. (+45)
79 [GO] 2022―Apr―01 Advanced cell therapy with low tissue factor loaded product NestaCell® does not confer thrombogenic risk for critically ill COVID-19 heparin-treated patients Rodrigo Pinheiro Araldi, Benedito Carlos Prezoto, Vivian Gonzaga, Bruna Policiquio, Thais Biude Mendes, Fernanda D’Amélio, et al. (+5)
80 [GO] 2022―Mar―25 Lithium salts as a treatment for COVID-19: pre-clinical outcomes O Soriano-Torres, E Noa Romero, NL González Sosa, JM Enríquez Puertas, A Fragas Quintero, M García Montero, et al. (+18)
81 [GO] 2022―Mar―21 Epidemiology, clinical ramifications, and cellular pathogenesis of COVID-19 mRNA-vaccination-induced adverse cardiovascular outcomes: A state-of-the-heart review Talal Almas, Sarah Rehman, Eyad Mansour, Tarek Khedro, Ali Alansari, Jahanzeb Malik, et al. (+17)
82 [GO] 2022―Mar―09 Potential inhibitor for blocking binding between ACE2 and SARS-CoV-2 spike protein with mutations Ming-Shao Tsai, Wei-Tai Shih, Yao-Hsu Yang, Yu-Shih Lin, Geng-He Chang, Cheng-Ming Hsu, et al. (+8)
83 [GO] 2022―Mar―08 Traditional Chinese medicine against COVID-19: Role of the gut microbiota Zhihua Yang, Yangxi Liu, Lin Wang, Shanshan Lin, Xiangdong Dai, Haifeng Yan, et al. (+5)
84 [GO] 2022―Feb―28 The potential role of resveratrol as supportive antiviral in treating conditions such as COVID-19 - A formulator’s perspective Roy van Brummelen, Anna C. van Brummelen
85 [GO] 2022―Feb―25 Ex-vivo Mucolytic and Anti-inflammatory Activity of BromAc in Tracheal Aspirates From COVID-19 Jordana Grazziela A. Coelho dos Reis, Geovane Marques Ferreira, Alice Aparecida Lourenço, A.Ágata Lopes Ribeiro, Camila Pacheco da Silveira Martins da Mata, Patrícia de Melo Oliveira, et al. (+33)
86 [GO] 2022―Feb―17 Efficacy of a multiple-indication antiviral herbal drug (Saliravira®) for COVID-19 outpatients: A pre-clinical and randomized clinical trial study Reza Ramazani Khorshiddoust, Saleh Ramazani Khorshiddoust, Tahereh Hosseinabadi, Faezeh Mottaghitalab, Farzad Mokhtari, Fatemeh Azadinia, et al. (+33)
87 [GO] 2022―Feb―14 Role of the renin-angiotensin system in NETosis in the coronavirus disease 2019 (COVID-19) Qingguang Zhang, Shang Ling, Kaili Hu, Jun Liu, Jin-Wen Xu
88 [GO] 2022―Feb―04 Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir Paul Andrei Negru, Andrei-Flavius Radu, Cosmin Mihai Vesa, Tapan Behl, Mohamed M. Abdel-Daim, Aurelia Cristina Nechifor, et al. (+5)
89 [GO] 2022―Jan―20 Natural products can be used in therapeutic management of COVID-19: Probable mechanistic insights Sabeeha Ali, Manzar Alam, Fatima Khatoon, Urooj Fatima, Abdelbaset Mohamed Elasbali, Mohd Adnan, et al. (+4)
90 [GO] 2022―Jan―19 Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine Thuy Trang Nguyen, Trang Ho Thu Quach, Thanh Mai Tran, Huynh Ngoc Phuoc, Ha Thi Nguyen, Tuong Kha Vo, Giau Van Vo
91 [GO] 2022―Jan―04 Targeting chronic COVID-19 lung injury; Tofacitinib can be used against tissue-resident memory T cells Sepideh Zununi Vahed, Seyed Mahdi Hosseiniyan Khatibi, Elham Ahmadian, Mohammadreza Ardalan
92 [GO] 2021―Dec―28 Mortality risk and antibiotic use for COVID-19 in hospitalized patients over 80 Andreea Rosca, Thibaut Balcaen, Audrey Michaud, Jean-Philippe Lanoix, Julien Moyet, Ingrid Marcq, et al. (+3)
93 [GO] 2021―Dec―25 Pulmonary Artery Targeted Therapy in Treatment of COVID-19 Related ARDS. Literature Review Oskar Puk, Aleksandra Nowacka, Klaudia Smulewicz, Katarzyna Mocna, Wiktor Bursiewicz, Natalia Kęsy, et al. (+2)
94 [GO] 2021―Dec―22 Impact of early interferon-β treatment on the prognosis of patients with COVID-19 in the first wave: A post hoc analysis from a multicenter cohort Sonsoles Salto-Alejandre, Zaira R. Palacios-Baena, José Ramón Arribas, Juan Berenguer, Jordi Carratalà, Inmaculada Jarrín, et al. (+4)
95 [GO] 2021―Dec―15 A critical analysis of the SARS-CoV-2 (COVID-19) pandemic, emerging variants, therapeutic interventions, and vaccination strategies Chang-Xing Li, Sobia Noreen, Li-Xue Zhang, Muhammad Saeed, Pei-Feng Wu, Muhammad Ijaz, et al. (+6)
96 [GO] 2021―Dec―10 Efficacy of mRNA, adenoviral vector, and perfusion protein COVID-19 vaccines Mohammad Reza Zinatizadeh, Peyman Kheirandish Zarandi, Maryam Zinatizadeh, Mohammad Hadi Yousefi, Jaffar Amani, Nima Rezaei
97 [GO] 2021―Dec―09 RdRp inhibitors and COVID-19: Is molnupiravir a good option? Seyed Mohammad Reza Hashemian, Mohammad Hossein Pourhanifeh, Michael R. Hamblin, Mohammad Karim Shahrzad, Hamed Mirzaei
98 [GO] 2021―Dec―09 Interaction of SARS-CoV-2 with cardiomyocytes: insight into the underlying molecular mechanisms of cardiac injury and pharmacotherapy Abdulhamid Abdi, Shahad AlOtaiby, Firas Al Badarin, Ali Khraibi, Hamdan Hamdan, Moni Nader
99 [GO] 2021―Dec―07 Plant lectins as prospective antiviral biomolecules in the search for COVID-19 eradication strategies Md. Nasir Ahmed, Rownak Jahan, Veeranoot Nissapatorn, Polrat Wilairatana, Mohammed Rahmatullah
100 [GO] 2021―Nov―12 Molecular pathways involved in COVID-19 and potential pathway-based therapeutic targets Masoumeh Farahani, Zahra Niknam, Leila Mohammadi Amirabad, Nasrin Amiri-Dashatan, Mehdi Koushki, Mohadeseh Nemati, et al. (+4)
101 [GO] 2021―Nov―12 Interleukin-6 in SARS-CoV-2 induced disease: Interactions and therapeutic applications Jamal Majidpoor, Keywan Mortezaee
102 [GO] 2021―Oct―28 Chemically Modified mRNA Beyond COVID-19: Potential Preventive and Therapeutic Applications for Targeting Chronic Diseases Dana Elkhalifa, Menatallah Rayan, Ahmed T. Negmeldin, Abdelbary Elhissi, Ashraf Khalil
103 [GO] 2021―Oct―22 A comprehensive review on efficient approaches for combating coronaviruses Mahdi Pouresmaieli, Elena Ekrami, Ali Akbari, Negin Noorbakhsh, Negin Borzooee Moghadam, Matin Mamoudifard
104 [GO] 2021―Oct―16 Role of Myeloid-derived suppressor cells in viral respiratory infections; Hints for Discovering Therapeutic Targets for COVID-19 Khadijeh Koushki, Maryam Salemi, Seyed Mohammad Miri, Yaser Arjeini, Mohsen Keshavarz, Amir Ghaemi
105 [GO] 2021―Oct―07 Metformin to decrease COVID-19 severity and mortality: Molecular mechanisms and therapeutic potential Olexandr Kamyshnyi, Victoriya Matskevych, Tetyana Lenchuk, Olha Strilbytska, Kenneth Storey, Oleh Lushchak
106 [GO] 2021―Oct―02 Sterilizing Immunity against COVID-19: Developing effective Helper T cells I and II activating vaccines Isaac Kyei-Barffour, Samuel Addo Akwetey, Enoch Aninagyei, George Ghartey-Kwansah, Desmond Omane Acheampong
107 [GO] 2021―Oct―02 Clinical drug therapies and biologicals currently used or in clinical trial to treat COVID-19 Rory J. Malek, Colin A. Bill, Charlotte M. Vines
108 [GO] 2021―Sep―27 Beneficial Effects of novel Aureobasidium Pullulans strains produced Beta-1,3-1,6 Glucans on Interleukin-6 and D-Dimer levels in COVID-19 patients; results of a randomized multiple-arm pilot clinical study Kadalraja Raghavan, Vidyasagar Devaprasad Dedeepiya, Vaddi Suryaprakash, Kosagi-Sharaf Rao, Nobunao Ikewaki, Tohru Sonoda, et al. (+5)
109 [GO] 2021―Sep―27 Role of microRNAs in COVID-19 with implications for therapeutics Nahid Arghiani, Tracy Nissan, Maryam M. Matin
110 [GO] 2021―Sep―22 A Digital Health Platform for Assisting the Diagnosis and Monitoring of COVID-19 Progression: An Adjuvant Approach for Augmenting the Antiviral Response and Mitigating the Immune-mediated Target Organ Damage Yuval Ishay, Assaf Potruch, Asaf Schwartz, Marc Berg, Khurram Jamil, Samuel Agus, Yaron Ilan
111 [GO] 2021―Sep―21 Cinnamon and its possible impact on COVID-19: The viewpoint of traditional and conventional medicine Maryam Yakhchali, Zahra Taghipour, Mehran Mirabzadeh Ardakani, Mahdi Alizadeh Vaghasloo, Mahdi Vazirian, Sima Sadrai
112 [GO] 2021―Sep―15 Arginine vasopressin and pathophysiology of COVID-19: An innovative perspective Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Safaa Qusti, Eida M. Alshammari, Francis O. Atanu, Gaber El-Saber Batiha
113 [GO] 2021―Sep―13 Neurokinin-1 Receptor as a potential drug target for COVID-19 treatment Riffat Mehboob
114 [GO] 2021―Sep―11 SARS-CoV-2 New Variants: Characteristic Features and impact on the Efficacy of Different Vaccines Abbas Khan, Taimoor Khan, Shughla Ali, Summiya Aftab, Yanjing Wang, Wang Qiankun, et al. (+7)
115 [GO] 2021―Sep―09 Nanoparticles as an Effective Drug Delivery System in Covid-19 Neehasri Kumar Chowdhuryz, Reshma Choudhury, Gaurav Ambadas Sonawane, Shankar Mavinamar, Xiaoming Lyu, Ramendra Pati Pandey, Chung-Ming Chang
116 [GO] 2021―Sep―02 Potential of herbal products in prevention and treatment of COVID-19. Literature review Aleksander Gajewski, Anna Kośmider, Aleksandra Nowacka, Oskar Puk, Michał Wiciński
117 [GO] 2021―Aug―30 Factors regulating dynamics of angiotensin-converting enzyme-2 (ACE2), the gateway of SARS-CoV-2: Epigenetic modifications and therapeutic interventions by epidrugs Suvasmita Rath, Venkateswarlu Perikala, Atala Bihari Jena, Jagneshwar Dandapat
118 [GO] 2021―Aug―27 Recent Advances in Management of COVID-19: A review Soraya Mouffak, Qamar Shubbar, Ekram Saleh, Raafat El-Awady
119 [GO] 2021―Aug―20 MMP-2 and MMP-9 levels in plasma are altered and associated with mortality in COVID-19 patients Carolina D`Avila-Mesquita, Ariel E.S. Couto, Ligia C.B. Campos, Tauana F. Vasconcelos, Jessyca M. Barbosa, Carlos A.C. Corsi, et al. (+16)
120 [GO] 2021―Aug―10 Repurposing methylene blue in the management of COVID-19: mechanistic aspects and clinical investigations Neha Dabholkar, Srividya Gorantla, Sunil Kumar Dubey, Amit Alexander, Rajeev Taliyan, Gautam Singhvi
121 [GO] 2021―Aug―05 COVID-19 challenges and its therapeutics Sabi Ur Rehman, Shaheed Ur Rehman, Hye Hyun Yoo
122 [GO] 2021―Aug―05 GB-2 Blocking the Interaction between ACE2 and Wild Type and Mutation of Spike Protein of SARS-CoV-2 Ming-Shao Tsai, Yao-Hsu Yang, Yu-Shih Lin, Geng-He Chang, Cheng-Ming Hsu, Reming-Albert Yeh, et al. (+7)
123 [GO] 2021―Jul―29 Interleukin-17A (IL-17A): a silent amplifier of COVID-19 Francesco Maione, Gian Marco Casillo, Federica Raucci, Cristian Salvatore, Giovanna Ambrosini, Luisa Costa, et al. (+3)
124 [GO] 2021―Jul―28 In silico drug repurposing in COVID-19: a network-based analysis Pasquale Sibilio, Simone Bini, Giulia Fiscon, Marialuisa Sponziello, Federica Conte, Valeria Pecce, et al. (+6)
125 [GO] 2021―Jul―28 Potential protective role of the anti-PD-1 blockade against SARS-CoV-2 infection Annoor Awadasseid, Qiang Yin, Yanling Wu, Wen Zhang
126 [GO] 2021―Jul―27 Kidney injury in COVID-19 patients, drug development and their renal complications: Review study Zeynab Mohamadi Yarijani, Houshang Najafi
127 [GO] 2021―Jul―27 A secondary approach with conventional medicines and supplements to recuperate current COVID-19 status Apu Chowdhury, Muhammad Sajid, Nabila Jahan, Temitope Isaac Adelusi, Pulak Maitra, Guolian Yin, et al. (+3)
128 [GO] 2021―Jul―23 Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2 Javier T. Granados-Riveron, Guillermo Aquino-Jarquin
129 [GO] 2021―Jul―14 Lecithinized superoxide dismutase in the past and in the present: Any role in the actual pandemia of COVID-19? Ilaria Farella, Raffaella Panza, Manuela Capozza, Nicola Laforgia
130 [GO] 2021―Jun―10 Role of toll-like receptor 7/8 pathways in regulation of interferon response and inflammatory mediators during SARS-CoV2 infection and potential therapeutic options Shetty Ravi Dyavar, Rahul Singh, Rohini Emani, Ganesh P. Pawar, Vinod D. Chaudhari, Anthony T. Podany, et al. (+3)
131 [GO] 2021―Jun―05 Identification of oligopeptides from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) non structural protein 8 (NSP8) and their similarities with type 1 angiotensin II receptor key sites Ammar Achour
132 [GO] 2021―May―28 Therapeutic use of specific tumour necrosis factor inhibitors in inflammatory diseases including COVID-19 Serena Patel, Meenu Wadhwa
133 [GO] 2021―May―27 CRISPR is a useful biological tool for detecting nucleic acid of SARS-CoV-2 in human clinical samples Md. Rashidur Rahman, Md. Amjad Hossain, Md. Mozibullah, Fateh Al Mujib, Afrina Afrose, Md. Shahed-Al-Mahmud, Md. Aminul Islam Apu
134 [GO] 2021―May―24 Theobroma cacao L. compounds: Theoretical study and molecular modeling as inhibitors of main SARS-CoV-2 protease Osvaldo Yañez, Manuel Isaías Osorio, Carlos Areche, Alejandro Vasquez-Espinal, Jessica Bravo, Angélica Sandoval-Aldana, et al. (+6)
135 [GO] 2021―May―18 Main Protease Inhibitors and Drug Surface Hotspots for the Treatment of COVID-19: A Drug Repurposing and Molecular Docking Approach Mahmudul Hasan, Md. Sorwer Alam Parvez, Kazi Faizul Azim, Md. Abdus Shukur Imran, Topu Raihan, Airin Gulshan, et al. (+4)
136 [GO] 2021―May―15 Corrigendum to: “Novel and emerging mutations of SARS-CoV-2: Biomedical implications” [Biomed. Pharmacother. 139 (2021) 111599] Elmira Mohammadi, Fatemeh Shafiee, Kiana Shahzamani, Mohammad Mehdi Ranjbar, Abbas Alibakhshi, Shahrzad Ahangarzadeh, et al. (+5)
137 [GO] 2021―May―06 COVID-19 and Metabolic Comorbidities: An Update on Emerging Evidences for Optimal Therapies Shuang Hua, Yong Yang, Danqi Zou, Jufei Li, Kaixuan Yan, Ying Xu, et al. (+3)
138 [GO] 2021―Apr―27 Disease-drug and drug-drug interaction in COVID-19: risk and assessment Devendra Kumar, Neerja Trivedi
139 [GO] 2021―Apr―23 Novel and emerging mutations of SARS-CoV-2: Biomedical implications Elmira Mohammadi, Fatemeh Shafiee, Kiana Shahzamani, Mohammad Mehdi Ranjbar, Abbas Alibakhshi, Shahrzad Ahangarzadeh, et al. (+5)
140 [GO] 2021―Apr―21 Resveratrol-zinc nanoparticles or pterostilbene-zinc: Potential COVID-19 mono and adjuvant therapy Mina T. Kelleni
141 [GO] 2021―Apr―08 Babaodan controls excessive immune responses and may represent a cytokine-targeted agent suitable for COVID-19 treatment Jing Qian, Hangdi Xu, Dongqing Lv, Wei Liu, Enguo Chen, Yong Zhou, et al. (+3)
142 [GO] 2021―Apr―06 Angiotensin II: A possible target for therapeutic intervention in COVID-19 Mohammad Rafi Khezri, Keyvan Yousefi, Morteza Ghasemnejad-Berenji
143 [GO] 2021―Apr―06 WILL CURCUMIN NANOSYSTEMS BE THE NEXT PROMISING ANTIVIRAL ALTERNATIVES IN COVID-19 TREATMENT TRIALS? Douglas Dourado, Danielle T. Freire, Daniel T. Pereira, Lucas Amaral-Machado, Éverton N. Alencar, André Luis Branco de Barros, E. Sócrates T. Egito
144 [GO] 2021―Apr―01 Identification of FDA Approved Drugs Against SARS-CoV-2 RNA Dependent RNA Polymerase (RdRp) and 3-chymotrypsin-like Protease (3CLpro), Drug Repurposing Approach Zahra Molavi, Sara Razi, Seyed Amir Mirmotalebisohi, Amirjafar Adibi, Marzieh Sameni, Farshid Karami, et al. (+10)
145 [GO] 2021―Mar―20 Efficacy of Brazilian Green Propolis (EPP-AF®) as an adjunct treatment for hospitalized COVID-19 patients: a randomized, controlled clinical trial Marcelo Augusto Duarte Silveira, David De Jong, Andresa Aparecida Berretta, Erica Batista dos Santos Galvão, Juliana Caldas Ribeiro, Thiago Cerqueira-Silva, et al. (+19)
146 [GO] 2021―Mar―18 Potential Therapeutic Agents to COVID-19: An Update Review on Antiviral Therapy, Immunotherapy, and Cell Therapy Mona Sadat Mirtaleb, Amir Hossein Mirtaleb, Hassan Nosrati, Jalal Heshmatnia, Reza Falak, Reza Zolfaghari Emameh
147 [GO] 2021―Mar―18 Impact of renin-angiotensin system inhibitors on mortality during the COVID Pandemic among STEMI patients undergoing mechanical reperfusion: Insight from an international STEMI registry Giuseppe De Luca, Miha Cercek, Lisette Okkels Jensen, Oliver Bushljetikj, Lucian Calmac, Tom Johnson, et al. (+61)
148 [GO] 2021―Mar―06 Antiviral activity of oleandrin and a defined extract of Nerium oleander against SARS-CoV-2 Kenneth S. Plante, Varun Dwivedi, Jessica A. Plante, Diana Fernandez, Divya Mirchandani, Nathen Bopp, et al. (+11)
149 [GO] 2021―Feb―26 Flavonoids against the SARS-CoV-2 induced inflammatory storm Alena Liskova, Marek Samec, Lenka Koklesova, Samson M. Samuel, Kevin Zhai, Raghad Khalid AL-Ishaq, et al. (+17)
150 [GO] 2021―Feb―25 Fluoxetine as an Anti-Inflammatory Therapy in SARS-CoV-2 Infection Justin Fortune Creeden, Ali Sajid Imami, Hunter M. Eby, Cassidy Gillman, Kathryn N. Becker, Jim Reigle, et al. (+5)
151 [GO] 2021―Feb―15 Heme oxygenase-1 inducer hemin does not inhibit SARS-CoV-2 virus infection Sheila Maestro, Karol M. Córdoba, Cristina Olague, Josepmaria Argemi, Matías A. Ávila, Gloria González-Aseguinolaza, et al. (+2)
152 [GO] 2021―Feb―06 Induced dysregulation of ACE2 by SARS-CoV-2 plays a key role in COVID-19 severity Maryam Eskandari Mehrabadi, Roohullah Hemmati, Amin Tashakor, Ahmad Homaei, Masoumeh Yousefzadeh, Karim Hemati, Saman Hosseinkhani
153 [GO] 2021―Feb―05 Research Progress of Traditional Chinese Medicine Against COVID-19 Wei Ren, Pan Liang, Yue Ma, Qin Sun, Qingrong Pu, Li Dong, et al. (+5)
154 [GO] 2021―Feb―05 An update review of emerging small-molecule therapeutic options for COVID-19 Dengke Tian, Yuzhi Liu, Chengyuan Liang, Liang Xin, Xiaolin Xie, Dezhu Zhang, et al. (+5)
155 [GO] 2021―Feb―05 Repurposing potential of Ayurvedic medicinal plants derived active principles against SARS-CoV-2 associated target proteins revealed by molecular docking, molecular dynamics and MM-PBSA studies Akalesh Kumar Verma, Vikas Kumar, Sweta Singh, Bhabesh Ch. Goswami, Ihosvany Camps, Aishwarya Sekar, et al. (+2)
156 [GO] 2021―Feb―03 SARS-CoV-2: From the pathogenesis to potential anti-viral treatments Peyman Kheirandish Zarandi, Mohammad Reza Zinatizadeh, Maryam Zinatizadeh, Mohammad Hadi Yousefi, Nima Rezaei
157 [GO] 2021―Jan―28 Stem cell therapy in COVID-19: Pooled evidence from SARS-CoV-2, SARS-CoV, MERS-CoV and ARDS: A systematic review Saniya Mahendiratta, Seema Bansal, Phulen Sarma, Harish Kumar, Gajendra Choudhary, Subodh Kumar, et al. (+3)
158 [GO] 2021―Jan―28 Targets and strategies for vaccine development against SARS-CoV-2 Jonaid Ahmad Malik, Almas Hanif Mulla, Tahmeena Farooqi, Faheem Hyder Pottoo, Sirajudheen Anwar, Kannan R.R. Rengasamy
159 [GO] 2021―Jan―28 Effective drugs used to combat SARS-CoV-2 infection and the current status of vaccines Annoor Awadasseid, Yanling Wu, Yoshimasa Tanaka, Wen Zhang
160 [GO] 2021―Jan―15 The Direct Evidence and Mechanism of Traditional Chinese Medicine Treatment of COVID-19 Xuedong An, YueHong Zhang, Liyun Duan, De Jin, Shenghui Zhao, RongRong Zhou, et al. (+3)
161 [GO] 2021―Jan―14 The role of iron in the pathogenesis of COVID-19 and possible treatment with lactoferrin and other iron chelators Hosam M. Habib, Sahar Ibrahim, Aamnah Zaim, Wissam H. Ibrahim
162 [GO] 2021―Jan―14 Human endeavor for anti-SARS-CoV-2 pharmacotherapy: a major strategy to fight the pandemic Ruixuan Wang, Preyesh Stephen, Yi Tao, Wenfa Zhang, Sheng-Xiang Lin
163 [GO] 2021―Jan―13 Impact of virus genetic variability and host immunity for the success of COVID-19 vaccines Wagner Gouvêa dos Santos
164 [GO] 2021―Jan―08 COVID-19 and inflammatory bowel disease: a pathophysiological assessment Chunxiu Yang, Shu-Yuan Xiao
165 [GO] 2021―Jan―08 Multifunctional Angiotensin Converting Enzyme 2, the SARS-CoV-2 Entry Receptor and Critical Appraisal of its Role in Acute Lung Injury Murat Oz, Dietrich Ernst Lorke
166 [GO] 2021―Jan―01 The neuropsychiatric manifestations of COVID-19: Interactions with psychiatric illness and pharmacological treatment Esmé Jansen van Vuren, Stephan F. Steyn, Christiaan B. Brink, Marisa Möller, Francois P. Viljoen, Brian H. Harvey
167 [GO] 2020―Dec―17 4-Aminoquinoline Compounds from the Spanish Flu to COVID-19 Roberto Barbosa Bazotte, Sandro Massao Hirabara, Tamires Afonso Duarte Serdan, Raquel Bragante Gritte, Talita Souza-Siqueira, Renata Gorjao, et al. (+5)
168 [GO] 2020―Dec―17 Could natural products modulate early inflammatory responses, preventing Acute Respiratory Distress Syndrome in COVID-19-confirmed patients? Lucas Amaral-Machado, Wógenes N. Oliveira, Victor M. Rodrigues, Nathan A. Albuquerque, Éverton N. Alencar, Eryvaldo S.T. Egito
169 [GO] 2020―Nov―28 Potential Effects of SARS-CoV-2 on the Gastrointestinal Tract and Liver Han-Yu Lei, Ying-He Ding, Kai Nie, Yin-Miao Dong, Jia-Hao Xu, Meng-Ling Yang, et al. (+6)
170 [GO] 2020―Nov―20 A traditional Chinese medicine formula NRICM101 to target COVID-19 through multiple pathways: a bedside-to-bench study Keng-Chang Tsai, Yi-Chia Huang, Chia-Ching Liaw, Chia-I Tsai, Chun-Tang Chiou, Chien-Jung Lin, et al. (+13)
171 [GO] 2020―Nov―17 Potential molecular targets of nonstructural proteins for the development of antiviral drugs against SARS-CoV-2 infection Xiao-huan Liu, Xiao Zhang, Zhen-hua Lu, You Shuang Zhu, Tao Wang
172 [GO] 2020―Nov―11 Prevention and treatment of COVID-19: focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine Bianza Moise Bakadia, Feng He, Tiatou Souho, Lallepak Lamboni, Muhammad Wajid Ullah, Biaou Ode Boni, et al. (+3)
173 [GO] 2020―Nov―11 SARS-CoV-2 microbiome dysbiosis linked disorders and possible probiotics role Ahmad Ud Din, Maryam Mazhar, Muhammad Wasim, Waqar Ahmad, Asma Bibi, Adil Hassan, et al. (+9)
174 [GO] 2020―Nov―05 Early use of Non-steroidal anti-inflammatory drugs in COVID-19 might reverse pathogenesis, prevent complications and improve clinical outcomes Mina T. Kelleni
175 [GO] 2020―Oct―23 Innate and adaptive immune responses against coronavirus Arezoo Hosseini, Vida Hashemi, Navid Shomali, Faezeh Asghari, Tohid Gharibi, Morteza Akbari, et al. (+2)
176 [GO] 2020―Oct―20 Targeting the SARS-CoV2 nucleocapsid protein for potential therapeutics using immuno-informatics and structure-based drug discovery techniques Alexander Kwarteng, Ebenezer Asiedu, Samuel Amoah Sakyi, Samuel Opoku Asiedu
177 [GO] 2020―Oct―19 Decoding the silent walk of COVID-19: Halting its spread using old bullets Mukesh Kumar, Jitender Madan, Rupinder Kaur Sodhi, Shashi Bala Singh, Anju Katyal
178 [GO] 2020―Oct―16 Potential of natural astaxanthin in alleviating the risk of cytokine storm in COVID-19 Jayanta Talukdar, Bhaskar Bhadra, Tomal Dattaroy, Vinod Nagle, Santanu Dasgupta
179 [GO] 2020―Sep―30 From the perspective of Traditional Chinese Medicine: treatment of mental disorders in COVID-19 survivors Ke Ma, Xin Wang, Shiyao Feng, Xia Xushan, Hongxiu Zhang, Abdul Rahaman, et al. (+8)
180 [GO] 2020―Sep―30 Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size Hong Zhao, Qi Zhu, Chi Zhang, Jiawen Li, Ming Wei, Yuhong Qin, et al. (+6)
181 [GO] 2020―Sep―17 CRISPR/Cas13: A potential therapeutic option of COVID-19 Melika Lotfi, Nima Rezaei
182 [GO] 2020―Sep―09 Male Predisposition to Severe COVID-19: Review of Evidence and Potential Therapeutic Prospects Desmond Omane Acheampong, Isaac Kyei Barffour, Alex Boye, Enoch Aninagyei, Stephen Ocansey, Martin Tangnaa Morna
183 [GO] 2020―Aug―28 The role of Interleukin 6 inhibitors in therapy of severe COVID-19 E. Nasonov, M. Samsonov
184 [GO] 2020―Aug―27 Can a metabolism-targeted therapeutic intervention successfully subjugate coronavirus? A scientific rational Kamran Mansouri, Mohsen Rastegari-Pouyani, Maryam Ghanbri-Movahed, Mehrnoush Safarzadeh, Sara Kiani, Zahra Ghanbari-Movahed
185 [GO] 2020―Aug―24 ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19 Mengzhen Dong, Jie Zhang, Xuefeng Ma, Jie Tan, Lizhen Chen, Shousheng Liu, et al. (+2)
186 [GO] 2020―Aug―24 Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2 Katya Uzunova, Elena Filipova, Velichka Pavlova, Toni Vekov
187 [GO] 2020―Aug―20 Candesartan could ameliorate the COVID-19 cytokine storm Abdel G. Elkahloun, Juan M. Saavedra
188 [GO] 2020―Aug―19 Lianhua Qingwen prescription for Coronavirus disease 2019 (COVID-19) treatment: advances and prospects Liu-Cheng Li, Zhi-Hui Zhang, Wen-Cheng Zhou, Jie Chen, Hua-Qian Jin, Hong-Mei Fang, et al. (+4)
189 [GO] 2020―Aug―17 Propolis and its potential against SARS-CoV-2 infection mechanisms and COVID-19 disease Andresa Aparecida Berretta, Marcelo Augusto Duarte Silveira, José Manuel Cóndor Capcha, David De Jong
190 [GO] 2020―Aug―13 SARS-CoV-2 neutralizing antibody levels are correlated with severity of COVID-19 pneumonia Wei Chen, Jie Zhang, Xijian Qin, Weixiao Wang, Miaomiao Xu, Lin-Fa Wang, et al. (+9)
191 [GO] 2020―Aug―01 Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies Arif Hussain, Anwarul Hasan, Mohammad Mahdi Nejadi Babadaei, Samir Haj Bloukh, Muhammad E.H. Chowdhury, Majid Sharifi, et al. (+2)
192 [GO] 2020―Jul―30 Existing highly accumulating lysosomotropic drugs with potential for repurposing to target COVID-19 Ulf Norinder, Astrud Tuck, Kalle Norgren, Vesna Munic Kos
193 [GO] 2020―Jul―28 Clinical efficacy of glucocorticoid on the treatment of patients with COVID-19 pneumonia: A single-center experience Yan Hu, Tingping Wang, Zhimin Hu, Xuan Wang, Zhengbin Zhang, Li Li, Peng Peng
194 [GO] 2020―Jul―28 SARS-CoV infection crosstalk with human host cell noncoding-RNA machinery: An in-silico approach Suresh K. Alahari, Hassan Yousefi, Arash Poursheikhani, Zahra bahmanpour, Mousa Vatanmakanian, Mohammad Taheri, Ladan Mashouri
195 [GO] 2020―Jul―17 PARP-inhibitors in a non-oncological indication as COVID-19: Are we aware about its potential role as anti-thrombotic drugs? The discussion is open Ettore Capoluongo
196 [GO] 2020―Jul―04 Clinical Retrospective Study on the Efficacy of Qingfei Paidu Decoction Combined with Western Medicine for COVID-19 Treatment Siyi Xin, Xueqi Cheng, Bo Zhu, Xiaolong Liao, Feng Yang, Lina Song, et al. (+13)
197 [GO] 2020―Jul―04 Outbreak of COVID-19: An emerging global pandemic threat Minhua Peng
198 [GO] 2020―Jul―03 Natural History of COVID-19 and Current Knowledge on Treatment Therapeutic Options Wagner Gouvea dos Santos
199 [GO] 2020―Jun―23 When science goes viral: The research response during three months of the COVID-19 outbreak Joanna Nowakowska, Joanna Sobocińska, Mateusz Lewicki, Żaneta Lemańska, Piotr Rzymski
200 [GO] 2020―Jun―19 STRATEGIES AND PERSPECTIVES TO DEVELOP SARS-CoV-2 DETECTION METHODS AND DIAGNOSTICS Rekha Jalandra, Amit K. Yadav, Damini Verma, Nishu Dalal, Minakshi Sharma, Rajeev Singh, et al. (+2)
201 [GO] 2020―Jun―19 Yidu-toxicity blocking lung decoction ameliorates inflammation in severe pneumonia of SARS-COV-2 patients with Yidu-toxicity blocking lung syndrome by eliminating IL-6 and TNF-a Jie Zhao, Xiaodong Yang, Chenghua Wang, Shuai Song, Kun Cao, Taohua Wei, et al. (+5)
202 [GO] 2020―May―30 Analysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19 by network pharmacology tools Qi Kong, Yue Wu, Yu Gu, Qi Lv, Feifei Qi, Shuran Gong, Xiuping Chen
203 [GO] 2020―May―25 Protection against COVID-19 injury by Qingfei Paidu decoction via anti-viral, anti-inflammatory activity and metabolic programming Jian Chen, Yong-kui Wang, Yuan Gao, Ling-San Hu, Jiang-wei Yang, Jian-ru Wang, et al. (+4)
204 [GO] 2020―May―14 Emerging pharmacotherapies for COVID-19 Rachana Salvi, Panini Patankar
205 [GO] 2020―May―13 Advances in the relationship between coronavirus infection and cardiovascular diseases Mengmeng Zhao, Menglong Wang, Jishou Zhang, Jing Ye, Yao Xu, Zhen Wang, et al. (+3)
206 [GO] 2020―Apr―28 New understanding of the damage of SARS-CoV-2 infection outside the respiratory system Yuhao Zhang, Xiuchao Geng, Yanli Tan, Qiang Li, Can Xu, Jianglong Xu, et al. (+5)
207 [GO] 2020―Apr―23 Occupational exposure to SARS-CoV-2 in burns treatment during the COVID-19 epidemic: Specific diagnosis and treatment protocol Zhifeng Huang, Donglin Zhuang, Bing Xiong, David Xingfei Deng, Hanhua Li, Wen Lai
 [1] 

207 Results       Page 1


[de][en]

Last change 2023―Oct―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.004 sec